Supplement: CRISPR in the Courthouse
An Interview with Law Professor Jacob Sherkow
Supplement: Pushing the Boundaries of CRISPR
Innovations in Genome Editing on Multiple Fronts
BioTrinity Conference Focuses on NextGen Healthcare
Meeting Highlights Array of Technologies and Promising Methodologies
Supplement: CRISPR Shakes Up Tools and Tech
Innovators Are Developing More Precise DNA-Cutting and Single-Cell-Seeding Platforms
For full access to this article login to GEN Select now.
Novel ADMET Technologies Gain Traction
- Too many new drug compounds fail in late-stage clinical trials due to inefficacy and safety concerns. With often-cited costs of $800 million to bring a new drug to market, a compelling need exists for improved early-stage screening. Insufficient knowledge of potential human toxicity can turn a promising lead candidate ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.